Millendo Therapeutics

Developing novel, disease-modifying treatments for endocrine diseases caused by hormone dysregulation

Millendo Therapeutics (formerly Atterocor) is developing a portfolio of treatments for endocrine disorders with limited or no approved treatment options. The company’s clinical-stage pipeline includes 1) MLE4901, an inhibitor of Neurokinin 3 receptor, to treat polycystic ovarian syndrome, and 2) ATR-101, an ACAT inhibitor, to treat adrenocortical carcinoma, congenital adrenal hyperplasia, and Cushing’s syndrome.

Year of Investment



Life Sciences


Development-Stage Therapeutics


Ann Arbor, Michigan